The funding will go toward created a summer program called the University of Houston Cardiovascular Undergraduate Research Experience, or UH-CURE. Photo via UH.edu

University of Houston professors have received a nearly $800,000 grant to create a new summer program that will support diverse future researchers.

The National Heart, Lung, and Blood Institute provided $792,900 in grant funding to Bradley McConnell, professor of pharmacology at the UH College of Pharmacy, and Tho Tran, research assistant professor of chemistry at the UH College of Natural Sciences and Mathematics.

The funding will go toward created a summer program called the University of Houston Cardiovascular Undergraduate Research Experience, or UH-CURE. Ten undergraduate students per year will be selected for five years in cardiovascular research across disciplinary lines.

"We are so grateful to be able to provide talented students across the U.S. an opportunity to experience our excellent cardiovascular research environment,” Tran says in a news release. “We want UH-CURE participants to gain confidence in their research abilities through our hands-on approach and the skillset to navigate future challenges through our professional training.”

The goal is to increase students’ interest in cardiovascular research, and students have the opportunity to receive a $6,000 stipend, travel to a globally recognized cardiovascular research conference, and take part in on-campus housing and a food allowance. The summer program will also try to develop research skills, increase awareness of transdisciplinary research, promote diversity and collaborations, cultivate transferable skills necessary for succeeding in graduate school and help facilitate undergraduate students to pursue further training in cardiovascular research.

The program will integrate students into a research lab where they will learn research skills, data analysis, and research integrity. The program will be under the mentorship of a faculty member from across UH’s colleges, and include workshop and enrichment activities.

McConnell and Tran previously formed the American Heart Association-funded UH-HEART pilot program, which focused on cardiovascular research. They expanded on that initiative with UH-CURE, which includes cardiovascular research across disciplinary lines from community engagement and population-based research to basic, translational, and applied research. UH-CURE also helps prepare for careers in cardiovascular research.

“We all know that a diverse environment leads to a much better generation of ideas and solutions,” Tran adds. “We hope to bring that strength to the future of cardiovascular research through our students.”

Tho Tran (left) and Bradley McConnell are professors at UH. Photo via UH.edu

Shaun Noorian, founder and CEO of Empower Pharmacy, joined InnovationMap for a Q&A on his rapidly growing compounding pharmacy business. Photo courtesy of Empower Pharmacy

Houston founder talks growth and innovation in the pharmaceuticals industry

Q&A

When Shaun Noorian encountered what he felt was a poorly ran process, as an engineer, he built something better. Now, he runs one of the nation's largest compounding pharmacies that's at a pivotal time for growth.

Headquartered in Houston, Empower Pharmacy is opening two new facilities locally — one debuts later this year and the other in 2022. Ahead of this milestone for his company, Noorian joined InnovationMap for a Q&A about how he decided to start his company and how he's grown it from a small office to two 85,000-square-foot facilities — as well as how Houston has been a big part of his company's success.

InnovationMap: Why did you decide to form Empower Pharmacy?

Shaun Noorian: I initially started Empower Pharmacy as a patient that was frustrated with the medication that I was receiving from a local compounding pharmacy in Houston.

I'd been working as a hydraulic fracturing field engineer at Schlumberger after graduating from college with a degree in mechanical engineering and was injured after several months on the job. I hemorrhaged three of my lower vertebrae and was put into physical therapy to try and fix my back. One of the doctors that was treating me noticed that I was very skinny for my age. I was probably 25 years old at the time. He decided to test my blood for the hormone testosterone, which is responsible for muscle growth and many other important factors in both men and women. The test determined that I had the testosterone level of an elderly man. The doctors sent me to Baylor College of Medicine for MRI blood tests, and they determined that I had a pituitary disorder and that I couldn't create the hormones responsible to tell my body to create testosterone. They put me on testosterone replacement therapy and it completely changed my life. Being testosterone deficient my entire life, I didn't realize what normal should be.When I was put on the medication, it was like a new lease on life. And I became very interested in the medication that I was taking, and how it worked. I studied everything I could. I was getting my medications from a local compounding pharmacy here in Houston, and I wasn't very satisfied with the quality of the service or the costs. Getting these medications was a very large percentage of my, what I was living off of. I couldn't figure out why this medication was so expensive when it cost just a few cents to make.

IM: How did you turn that passion into a business?

SN: I guess like most engineers, I decided I wanted to build — to make my own pharmacy. And make my own drugs and offer them to patients in a manner that I would want to it be from a patient's perspective when dealing with the compound pharmacy. I leased about 100 square feet in the back of the doctor's office. I pretty much converted one of his exam rooms and started my pharmacy there. I hired a pharmacist and did all the technician duties myself. I wanted to apply the patient experience that I would've wanted.

Slowly but surely, patients and prescribers around the area were very happy with the level of service and quality that they were receiving from our pharmacy. And we would get more requests through simple word of mouth and reputation. We grew pretty quickly out of that space and then built out a 1,500-square-foot space in a shopping center a couple of years later.

Following several more expansions and new locations throughout the years, we're now gearing up to open our new facility (7601 N. Sam Houston Parkway W., near the intersection of Highway 249 and Beltway 8), which will be the most advanced compounding pharmacy ever built. It has a lot of automation, and utilizes the same processes and equipment that Big Pharma uses to make their drugs. We're trying to better the system and continue to bring automation into the compounding industry so we can continue to scale and set a standard for the rest of the industry.

IM: What sets your business apart from what else is out there?

SN: We're a pharmacy that wants to do everything in house. We want to integrate our supply chain, and that means removing low value middleman from the health care ecosystem and streamline the medical distribution process. This means being the manufacturer, distributor, and regional pharmacy all in one, so we can really control our supply chain and integrate it. And at the same time, we can really be able to control and customize the consumer experience for both our patients and prescribers in a way that we would want. It's been a lot of fun being able to create your own healthcare ecosystem and building software for that your for patients that I'd want to use.

I'm an engineer. It's more fun talking about my equipment than anything else.

If you walk into a Walgreens, it's a simple repackaging operation. You're taking pills from a big bottle and putting them in a smaller bottle. What differentiates us from them and what's unique about this facility is that it's really built the same way as traditional pharmaceutical manufacturing is built using the same exact processes, systems, layout, etc.

We create our own purified water. We create our own clean, dry compressed air. We create our own clean steam that we use in our compounding processes, which are built to CGMP — current good manufacturing practices — specifications. We adopt a lot of those processes into the facility, and we built the facility around those standards that the FDA requires.

IM: You mentioned a new facility — but Empower is actually opening two new facilities within a year of each other. Tell me about those.

SN: Each facility is a mirror of each other — they are both 85,000 square feet. The one that's opening this year is going to be a pharmacy, so it'll just be dealing with patients. The next one is going to be licensed with the FDA and will work with larger institutions, selling medications in bulk for office use to institutions, hospitals, clinics, and prescribers. They will administer those medications to their patients in office. It's our way of being able to integrate that supply chain, so we can be that one-stop shop. So, physicians don't have to go to different vendors to source their medications — we can be an all-encompassing partner and vendor for them to source all their medical needs.

IN: How else are you expanding your business model?

SN: We've always concentrated on — since the inception of the company — quality, service, and cost. And we're always working to figure out how to increase quality, how to decrease costs, and how to make it easier and more convenient for our customers to use us. Some projects that we've been working on that are set to launch in the next few years is building out our own API – application programming interface – so that our telemedicine and other clients that are using electronic versions of health care record software can easily interface with our systems and vice versa.

IM: How has Houston been for you as a home base for Empower?

SN: I think being in Houston is one of the reasons why we've grown to become the largest compounding pharmacy in the nation. It's really just a lot of luck of being in Houston. I'm sure we're all aware that having the largest medical center in the world in your own backyard is a great way to have more prescribers than pretty much any other city in the country. That definitely helped us and continues to help us grow. Additionally, being the third largest city by population means we have a large workforce to pull a diverse workforce for whatever this company needs. Having a diverse workforce has been integral in our growth. Also, having two schools of pharmacy in our backyard has also helped.

There's a reason why, as we grow, we always stay in Houston. It doesn't make sense for us to go anywhere else. This is a great city and a great state to do business.

IM: Are you hiring?

Oh, we're always hiring. I think we currently have around 50 positions open and there's everything from pharmacy operations, all the way to manufacturing and marketing to sales, logistics, legal, you name it.

------

This conversation has been edited for brevity and clarity.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Innovative Houston-area hardtech startup closes $5M seed round

fresh funding

Conroe-based hardtech startup FluxWorks has closed a $5 million seed round.

The funding was led by Austin-based Scout Ventures, which invests in early-stage startups working to solve national security challenges.

Michigan Capital Network also contributed to the round from its MCN Venture Fund V. The fund is one of 18 selected by the Department of Defense and Small Business Administration to participate in the Small Business Investment Company Critical Technologies Initiative, which will invest $4 billion into over 1,700 portfolio companies.

FluxWorks reports that it will use the funding to drive the commercialization of its flagship Celestial Gear technology.

"At Scout, we invest in 'frontier tech' that is essential to national interest. FluxWorks is doing exactly that by solving critical hardware bottlenecks with its flagship Celestial Gear technology ... This is about more than just gears; it’s about strengthening our industrial infrastructure," Scout Ventures shared in a LinkedIn post.

Fluxworks specializes in making contactless magnetic gears for use in extreme conditions, which can enhance in-space manufacturing. Its contactless design leads to less wear, debris and maintenance. Its technology is particularly suited for space applications because it does not require lubricants, which can be difficult to control at harsh temperatures and in microgravity.

The company received a grant from the Texas Space Commission last year and was one of two startups to receive the Technology in Space Prize, funded by Boeing and the Center for the Advancement of Science in Space (CASIS), in 2024. It also landed $1.2 million through the National Science Foundation's SBIR Phase II grant this fall.

Fluxworks was founded in College Station by CEO Bryton Praslicka in 2021. Praslicka moved the company to Conroe 2024.

5 Houston scientists named winners of prestigious Hill Prizes 2026

prized research

Five Houston scientists were recognized for their "high-risk, high-reward ideas and innovations" by Lyda Hill Philanthropies and the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

The 2026 Hill Prizes provide seed funding to top Texas researchers. This year's prizes were given out in seven categories, including biological sciences, engineering, medicine, physical sciences, public health and technology, and the new artificial intelligence award.

Each recipient’s institution or organization will receive $500,000 in direct funding from Dallas-based Lyda Hill Philanthropies. The organization has also committed to giving at least $1 million in discretionary research funding on an ad hoc basis for highly-ranked applicants who were not selected as recipients.

“It is with great pride that I congratulate this year’s Hill Prizes recipients. Their pioneering spirit and unwavering dedication to innovation are addressing some of the most pressing challenges of our time – from climate resilience and energy sustainability to medical breakthroughs and the future of artificial intelligence,” Lyda Hill, founder of Lyda Hill Philanthropies, said in a news release.

The 2026 Houston-area recipients include:

Biological Sciences: Susan M. Rosenberg, Baylor College of Medicine

Rosenberg and her team are developing ways to fight antibiotic resistance. The team will use the funding to screen a 14,000-compound drug library to identify additional candidates, study their mechanisms and test their ability to boost antibiotic effectiveness in animal models. The goal is to move toward clinical trials, beginning with veterans suffering from recurrent infections.

Medicine: Dr. Raghu Kalluri, The University of Texas MD Anderson Cancer Center

Kalluri is developing eye drops to treat age-related macular degeneration (AMD), the leading cause of vision loss globally. Kalluri will use the funding to accelerate studies and support testing for additional ocular conditions. He was also named to the National Academy of Inventors’ newest class of fellows last month.

Engineering: Naomi J. Halas, Rice University

Co-recipeints: Peter J. A. Nordlander and Hossein Robatjazi, Rice University

Halas and her team are working to advance light-driven technologies for sustainable ammonia synthesis. The team says it will use the funding to improve light-driven catalysts for converting nitrogen into ammonia, refine prototype reactors for practical deployment and partner with industry collaborators to advance larger-scale applications. Halas and Nordlander are co-founders of Syzygy Plasmonics, and Robatjazi serves as vice president of research for the company.

The other Texas-based recipients include:

  • Artificial Intelligence: Kristen Grauman, The University of Texas at Austin
  • Physical Sciences: Karen L. Wooley, Texas A&M University; Co-Recipient: Matthew Stone, Teysha Technologies
  • Public Health: Dr. Elizabeth C. Matsui, The University of Texas at Austin and Baylor College of Medicine
  • Technology: Kurt W. Swogger, Molecular Rebar Design LLC; Co-recipients: Clive Bosnyak, Molecular Rebar Design, and August Krupp, MR Rubber Business and Molecular Rebar Design LLC

Recipients will be recognized Feb. 2 during the TAMEST 2026 Annual Conference in San Antonio. They were determined by a committee of TAMEST members and endorsed by a committee of Texas Nobel and Breakthrough Prize Laureates and approved by the TAMEST Board of Directors.

“On behalf of TAMEST, we are honored to celebrate the 2026 Hill Prizes recipients. These outstanding innovators exemplify the excellence and ambition of Texas science and research,” Ganesh Thakur, TAMEST president and a distinguished professor at the University of Houston, added in the release. “Thanks to the visionary support of Lyda Hill Philanthropies, the Hill Prizes not only recognize transformative work but provide the resources to move bold ideas from the lab to life-changing solutions. We are proud to support their journeys and spotlight Texas as a global hub for scientific leadership.”

Investment bank opens new Houston office focused on energy sector

Investment bank Cohen & Co. Capital Markets has opened a Houston office to serve as the hub of its energy advisory business and has tapped investment banking veteran Rahul Jasuja as the office’s leader.

Jasuja joined Cohen & Co. Capital Markets, a subsidiary of financial services company Cohen & Co., as managing director, and head of energy and energy transition investment banking. Cohen’s capital markets arm closed $44 billion worth of deals last year.

Jasuja previously worked at energy-focused Houston investment bank Mast Capital Advisors, where he was managing director of investment banking. Before Mast Capital, Jasuja was director of energy investment banking in the Houston office of Wells Fargo Securities.

“Meeting rising [energy] demand will require disciplined capital allocation across traditional energy, sustainable fuels, and firm, dispatchable solutions such as nuclear and geothermal,” Jasuja said in a news release. “Houston remains the center of gravity where capital, operating expertise, and execution come together to make that transition investable.”

The Houston office will focus on four energy verticals:

  • Energy systems such as nuclear and geothermal
  • Energy supply chains
  • Energy-transition fuel and technology
  • Traditional energy
“We are making a committed investment in Houston because we believe the infrastructure powering AI, defense, and energy transition — from nuclear to rare-earth technology — represents the next secular cycle of value creation,” Jerry Serowik, head of Cohen & Co. Capital Markets, added in the release.

---

This article originally appeared on EnergyCaptialHTX.com.